Gossamer Bio Inc’s (GOSS) Quiet Period To End on March 20th

Gossamer Bio’s (NASDAQ:GOSS) quiet period is set to end on Wednesday, March 20th. Gossamer Bio had issued 17,250,000 shares in its IPO on February 8th. The total size of the offering was $276,000,000 based on an initial share price of $16.00. During Gossamer Bio’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities analysts have commented on GOSS shares. Bank of America started coverage on Gossamer Bio in a research note on Tuesday, March 5th. They set a “buy” rating and a $30.00 price objective on the stock. Barclays started coverage on Gossamer Bio in a research note on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price objective on the stock. Leerink Swann started coverage on Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating on the stock. Svb Leerink started coverage on Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Evercore ISI started coverage on Gossamer Bio in a research note on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $29.25.

Gossamer Bio stock opened at $20.48 on Friday. Gossamer Bio has a one year low of $16.00 and a one year high of $25.06.

In other Gossamer Bio news, CFO Bryan Giraudo bought 6,000 shares of Gossamer Bio stock in a transaction on Tuesday, February 12th. The shares were purchased at an average price of $16.00 per share, with a total value of $96,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Russell J. Cox bought 7,200 shares of Gossamer Bio stock in a transaction on Tuesday, February 12th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $115,200.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 14,750 shares of company stock worth $236,000.

WARNING: “Gossamer Bio Inc’s (GOSS) Quiet Period To End on March 20th” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2019/03/17/gossamer-bio-incs-goss-quiet-period-to-end-on-march-20th.html.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: How to interpret a stock’s beta number

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.